Pliant Therapeutics (NASDAQ:PLRX) announced that, following a recommendation by the Data Safety Monitoring Board (DSMB), it will convene an independent panel of experts in pulmonary diseases and biostatistics to review data from the BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).
According to Pliant, the decision to assemble an outside panel was made after its own review of blinded data failed to clarify the DSMB’s rationale for recommending a pause in trial dosing and enrollment.
The company stated that it voluntarily halted enrollment and dosing in the BEACON-IPF Phase 2b trial and remains committed to maintaining blinding to preserve data integrity, ensuring the trial’s potential as a registrational trial.
